Skin Cancer is the most common cancer in the United States with over 5 million cases diagnosed each year.

An insidious interloper now often comes between me and my patients. I’m talking about pharmacy benefit managers (PBMs), the middlemen that have introduced a bureaucratic and nightmarish system of delays and denials into filling prescriptions.

At the Community Oncology Alliance (COA) Annual Meeting (April 4-5, 2019; Orlando, FL), Journal of Clinical Pathways sat down with three of the leaders of OneOncology – a new partnership of independent community oncology practices that is physician-driven and utilizes a unified platform to enable physicians to care for patients through the entire course of care.

Head and neck cancer are a group of cancers that starts in the mouth, nose, throat, larynx, sinuses, or salivary glands.

COA Applauds the Senate Finance Committee for PBM Hearing as Part of National Efforts to Shed Light on PBM Abuses and Lower Drug Prices More Investigation and Oversight Needed to Examine Adverse Impact of PBM Abuses on Patient Care

Statement from Ted Okon executive director of the Community Oncology Alliance

According to urologyhealth.org, testicular cancer is the most common cancer found in males ages 15-34, with 9,560 diagnosed this year.

On Monday, March 25, New York Cancer & Blood Specialists “NYCBS” unveiled its brand new Varian Halcyon Linear Accelerator at its Eastchester Center for Cancer Care.

According to Cancer.org, there are 73,820 new cases of kidney cancer (44,120 in men and 29,700 in women) will occur, while 14,770 people (9,820 men and 4,950 women) will die from this disease.

New York Cancer & Blood Specialists (NYCBS) welcomes Dr. Richard Zuniga to its practice of physicians as a board certified hematologist-oncologist.

Dr. Zuniga has been practicing medicine for the past 11 years. He practiced as an Attending Physician and then became the Medical Director of Clinical Research at Lowell General Hospital. He has also practiced at New York Methodist Hospital, where he received the Attending Teaching Excellence Award in 2015.

The patient had metastatic kidney cancer, and his oncologist was seeking to treat him with sunitinib malate (Sutent, Pfizer), a preferred first-line oral therapy. But the patient’s pharmacy benefit manager (PBM) refused to cover the cost of the medication. The PBM told the oncologist that the patient’s kidney must first be removed.

However, the patient’s surgeon had already determined that the patient was not a surgical candidate, owing to the extent of his disease and to coexisting medical conditions.